Video

ASH 2021: Novel Therapy in Acute Lymphocytic Leukemia

Author(s):

Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute,Jae Park, MD, Memorial Sloan Kettering Cancer Center

Expert perspectives on clinical data readouts in acute lymphocytic leukemia from the ASH 2021 annual meeting.

Data from the following clinical trials are discussed:

  • 1233: Updated results from a phase I study of hyper-CVAD with sequential blinatumomab in adults with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia
  • 1231: Superior overall survival with blinatumomab versus chemotherapy as pre-transplant consolidation treatment in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL): longer follow-up (FU) of a phase 3 randomized controlled trial (RCT)
  • 4028: Successful outpatient administration of blinatumomab infusion in pediatric patients with acute lymphoblastic leukemia
  • 516: Isatuximab in combination with chemotherapy in pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia (ISAKIDS): interim analysis
  • 428: Real-world outcomes for pediatric and young adult patients with relapsed refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel: update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Supported in part by Takeda Oncology. Content developed independently by Onclive®.

Related Videos
Ashkan Emadi, MD, PhD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Eunice S. Wang, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Eunice Wang, MD, and Chandler Park, MD, FACP
Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Related Content
Ashkan Emadi, MD, PhD
December 20th 2024

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

CP-CML | Image Credit: © สุพัฒตรา แสนพลี – stock.adobe.com
December 19th 2024

Olverembatinib Demonstrates Efficacy and Safety in Heavily Pretreated CP-CML

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

FDA
December 18th 2024

FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease

Orca-Q in Hematologic Malignancies | Image Credit: © Tatiana Shepeleva - stock.adobe.com
December 16th 2024

Orca-Q Leads to Low Rates of GVHD, Non-Relapse Mortality in High-Risk Hematologic Malignancies After Allo-HCT